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and together with Russian and international colleagues to carry out a number of studies that have influenced its development. In this regard, with the example of some of these studies, I will try to give my vision of the historical context and trends in the development of nanomedicine and drug delivery.
The nanomedicine approach is based on the use of nano-sized supramolecular particles as containers for the delivery of biologically active substances. By the end of the 80s, when we were just starting our work in this field, liposomes were actively studied and they were the first nanopreparations, applied in the clinic.
Liposomes have an internal water reservoir, which is well used for the inclusion of hydrophilic substances delivered (for example, doxorubicin in the anticancer drug Doxil). However, with some exceptions, they are not very well suited for delivery of hydrophobic substances. The reason is that in the lipid bilayer, which is the basis of the vesicular structure of liposomes, there is usually not too much room for hydrophobic compounds to be included without a significant change in the structure of this bilayer.
A successful alternative for the inclusion of hydrophobic substances were micelles of amphiphilic block copolymers. In such micelles, insoluble polymer chains (blocks) form a hydrophobic core, and hydrophilic blocks create a water-soluble corona that retains micelles in the dissolved (dispersed) state. The polymer chains in the hydrophobic core of the micelle have sufficient "mobility" and can "make room" to include a significant amount of waterinsoluble drug compounds without significantly altering the overall structure of the micelle (core-corona). In the late 80-ies we carried out research in collaboration with V.P. Chekhonin and other colleagues and we used polymeric micelles for the brain-targeted delivery of non-covalently incorporated ("solubilized") biologically active substances for the first time . Soon this field got a widespread development and was continued by the efforts of many laboratories, including ours, as well as prof. K. Kataoka in Japan and many others. Today, over a dozen of polymeric micelles-based drugs are in clinical trials and one drug developed in Korea, Genexol PM, has been approved for use in the treatment of breast, lung (NSCLC) and ovarian cancer.
In this regard, it should be mentioned that the world's first polymeric micelles-based drug, tested in the clinic was SP1049C, containing doxorubicin in micelles of poloxamers (also known as "Pluronic"), which we developed together with V.Yu. Alakhov and Supratek Pharma (Canada) . The concept of this drug was based on the phenomenon of a significant increase in the sensitivity of cancer cells resistant to therapy under the influence of poloxamers (Pluronics) of a certain structure (Alakhov et al., 1996) . We established the mechanisms of this phenomenon, including the interaction of poloxamers with membrane pumps and the mitochondrial respiratory chain (Batrakova et al., 2001; Alakhova et al., 2010) , and showed that this drug effectively kills not only multidrug-resistant tumors, but also tumor-initiating cells, and, on the whole, significantly increases the effectiveness of For example, we recently created paclitaxel preparations in which the drug's effective load exceed the drug content in Abraxan and Taxol, respectively, 10 and 100 times. Due to a sharp decrease in the content of polymer carriers and the possibility of increasing the concentration of the drug administered, the safe dose of the drug also significantly increases, which makes it possible to enhance the therapeutic effect (He et al., 2016) . In animal models, the possibility of simultaneous administration of several chemotherapeutic drugs included in one micellar container is shown, which not only simplifies the practical application of combined chemotherapy "in one", but also increases the effectiveness of these drugs by simultaneously delivering them to tumor cells.
Close to these studies are adjacent studies in the field of nano-gels and cross-linked polymeric micelles as drug delivery containers. We first used nano-gels from covalently linked polymer chains to deliver oligonucleotides, and then developed this approach for low molecular weight compounds, for example, cisplatin derivatives and combinations of these derivatives with other drugs (Vinogradov et al., 2002; Kabanov, Vinogradov, 2009 ).
By introducing chemical crosslinks between polymer chains the stability of the particle delivered in the body is achieved. By using bio-cleavable crosslinks it is possible to achieve controlled drug-release and destruction of the container at the end of its operation. Due to the stability of such a container in the body, it is possible to address it by antibodies or other biospecific molecules attached to the container (Nukolova et al., 2011 (Nukolova et al., , 2013 ).
An important role is played by the fact that nano-gels, swollen in water and polymeric micelles are poorly adsorbed on the surface of non-target cells, which improves the specificity of their delivery to target cells. In addition, by varying the number of cross-links it is possible to vary the swelling of nano-gels and their elasticity, which in principle can be used to improve their penetration into the tumor.
Returning to the origins of our work in the field of nanomedicine back into the late 80-ies in cooperation with V.A. Kabanov and V.I. Kiselev, we showed the possibility of packaging plasmid DNA by forming a polyelectrolyte DNA complex with polycations for the purpose of cell delivery (Kabanov et al., , 1993 . Such compact nanoscale complexes were subsequently called "polyplexes", and they were prototypes of modern polycation -based cell transfection systems, which are now very widely used in laboratories.
However, the limitation of such system was that to ensure the stability of polyplex nanoparticles in aqueous media it is necessary to add a large excess of polycation, which increases the toxicity of polyplexes, and, most importantly, makes it difficult to use them in a living organism due to the adsorption of seum proteins and aggregation of such particles in the blood.
The key solution was to use cationic block copolymers containing uncharged water-soluble chains such as, for example, polyethylene glycol (Kabanov et al., 1995) . As a result, it became possible to obtain uncharged nanoscale polyelectrolyte micelles with a core of mutually neutralized nucleic acids and polycations and a corona of uncharged polymer chains. We called Thus, in animal models of Parkinson's disease, a reduction in inflammation is achieved and a significant neuroprotective effect is observed, which is expressed in the preservation of dopaminergic neurons (Brynskikh et al., 2010) .
The use of macrophages as drug delivery systems is counterintuitive for nanomedicine. In all the early works in this field, the task was to create such nanopreparations that would avoid capture by macrophages, acting as "cleaners" of the organism from alien objects. At the same time, already during the work on the mechanism of delivery of the "bare" plasmid DNA after its injection into the skeletal muscle, we noticed that in the phenomenon of a sharp increase in the expression of genes in the presence of poloxamers (Lemieux et al., 2000; Yang et al., 2005 ) an important role is played by cells of the immune system and, first of all, macrophages.
It turned out that when injected into the muscle with DNA, along with the poloxamer, which acts as a kind of "adjuvant" that activates the cells of the immune system, macrophages efficiently capture DNA, and not only transmit it to muscle cells, but can deliver it to distant organs from the injection site, in particular the lymph nodes and spleen (Gaymalov et al., 2009) were administered to animals. In both cases, the macrophages administered into the bloodstream not only migrated to the brain, delivering the corresponding genes, but also ensured the effective expression of these genes, leading to significant neuroprotection (Haney et al., 2013; Zhao et al., 2014) . (Klyachko et al., 2012) . It has also recently been established that within this "magneto-mechanical" approach, using an ultra-low frequency field of 50 Hz, it is possible to act on the cell from the inside, in particular, to destroy the cytoskeleton of cancer cells into which magnetic nanoparticles are preliminarily delivered (Master et al., 2016) . Remarkably, the destruction of the cytoskeleton in normal epithelial cells does not occur, but occurs in cancerous cells because they have a less stable cytoskeleton.
Thus, the principle possibility of selective remote action on cancer cells with the help of external magnetic fields has been demonstrated.
It is hoped that this and other similar approaches will be substantially developed in the nearest future and will lead to improving methods of diagnosing and treating human diseases.
